University of Zagreb researcher Beata Halassy treated her breast cancer with an unproven virus-based therapy using viruses ...

It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal ... Fast Track designation for the treatment of ER+/HER2- metastatic ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

More people are getting cancer in their 20s, 30s, and 40s, and surviving, thanks to rapid advancement in care. Many will have ...

Source: Getty Images Phase 2 trial results support further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer, according to researchers. The ...

While losing some of her hair during chemotherapy treatment ... progesterone receptor-positive and HER2-positive. After skin cancer, breast cancer is the second most common cancer among women ...